Monoclonal antibodies (mAbs) are the fastest-growing segment of the pharmaceutical market (Compound Annual Growth Rate = 14%) with estimated global sales of $40 billion in 2009 and products targeting infectious, autoimmune and oncology diseases.

ImmuneXcite has developed a proprietary platform technology for enhancing the efficacy of therapeutic monoclonal antibodies for oncological and infectious disease targets.